655 Shares in Medpace Holdings, Inc. $MEDP Acquired by City Center Advisors LLC

Key Points

• City Center Advisors LLC acquired 655 shares of Medpace Holdings, valued at approximately $206,000, during the 2nd quarter.
• Recent analyst reports have shown mixed ratings for Medpace, with Cowen and UBS Group downgrading their ratings to "sell", while Deutsche Bank raised its target price to $430.00.
• Insider activity saw significant sales, with VP Susan E. Burwig selling 10,000 shares for $4.8 million and CFO Kevin M. Brady selling 12,000 shares for $5.45 million, indicating a reduction in their stock ownership.

City Center Advisors LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 655 shares of the company's stock, valued at approximately $206,000.

Several other hedge funds have also recently bought and sold shares of the stock. Voya Investment Management LLC lifted its stake in Medpace by 7.6% in the 1st quarter. Voya Investment Management LLC now owns 21,976 shares of the company's stock valued at $6,696,000 after acquiring an additional 1,560 shares in the last quarter. Militia Capital Partners LP raised its stake in shares of Medpace by 3,839.4% during the 1st quarter. Militia Capital Partners LP now owns 13,000 shares of the company's stock worth $3,961,000 after purchasing an additional 12,670 shares in the last quarter. Inspire Investing LLC bought a new stake in shares of Medpace during the 1st quarter worth approximately $2,059,000. Strs Ohio bought a new stake in shares of Medpace during the 1st quarter worth approximately $10,055,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent analyst reports. Cowen lowered Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. UBS Group lowered Medpace from a "neutral" rating to a "sell" rating and boosted their target price for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. William Blair reissued a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their target price on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Finally, Rothschild & Co Redburn lowered Medpace from a "buy" rating to a "neutral" rating and boosted their target price for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and an average price target of $422.27.

Insider Activity at Medpace

In other news, VP Susan E. Burwig sold 10,000 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares of the company's stock, valued at approximately $27,600,000. This represents a 14.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $2,725,380. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 161,266 shares of company stock worth $74,111,427 in the last quarter. 20.30% of the stock is currently owned by corporate insiders.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $490.64 on Friday. The stock's fifty day moving average price is $429.46 and its two-hundred day moving average price is $349.27. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $501.30. The firm has a market cap of $13.78 billion, a price-to-earnings ratio of 36.48, a P/E/G ratio of 3.13 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same period in the prior year, the firm posted $2.75 EPS. The company's revenue for the quarter was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.